Notice of Results

Oxford Biomedica PLC
30 June 2004


IMMEDIATE RELEASE                                                 30 JUNE 2004


                              OXFORD BIOMEDICA PLC

                           Notice of Interim results

                       For the six months ended 30 June 2004


Oxford, UK: 30 June 2004 - Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announces that the company will be releasing its interim
results for the six months ended 30 June 2004 on Wednesday 1 September 2004.


Meetings:

An Analyst briefing will be held at 10:00 am on the day followed by a press
briefing which will commence at 11:30 am. The venue for both meetings will be
Buchanan Communications, 107 Cheapside, London EC2V 6DN.


                                     -Ends-

For further information, please contact:

Oxford BioMedica plc                                   Tel: [phone]
Professor Alan Kingsman, Chief Executive

City/Financial Enquiries:
Lisa Baderoon/ Mark Court: Buchanan Communications     Tel: [phone]



Notes to editors

Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.


In addition to its technical expertise in gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing know-how. The development
pipeline includes two novel anti-cancer products in clinical trials; and two
neurotherapy products in advanced preclinical development for Parkinson's
disease and retinopathy. The Company is underpinned by an extensive preclinical
and research portfolio and about 70 patent families, which represents one of the
broadest patent estates in the field.


The Company has a staff of about 65 split between its main facilities in Oxford 
and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford
BioMedica has corporate collaborations with Wyeth, Intervet, Merck & Co,
Amersham and Kiadis.


Further information is available at http://www.oxfordbiomedica.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange